Adaptimmune Therapeutics (NASDAQ:ADAP) Now Covered by StockNews.com
StockNews.com started coverage on shares of Adaptimmune Therapeutics (NASDAQ:ADAP – Free Report) in a research report released on Thursday. The firm issued a buy rating on the biotechnology company’s stock. Other equities research analysts also recently issued reports about the company. HC Wainwright lowered their target price on Adaptimmune Therapeutics from $4.00 to $3.50 and […]
StockNews.com started coverage on shares of Adaptimmune Therapeutics (NASDAQ:ADAP – Free Report) in a research report released on Thursday. The firm issued a buy rating on the biotechnology company’s stock. Other equities research analysts also recently issued reports about the company. HC Wainwright lowered their target price on Adaptimmune Therapeutics from $4.00 to $3.50 and […]
